J
Justin Guinney
Researcher at Sage Bionetworks
Publications - 129
Citations - 21754
Justin Guinney is an academic researcher from Sage Bionetworks. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 32, co-authored 97 publications receiving 12819 citations. Previous affiliations of Justin Guinney include Duke University & University of Washington.
Papers
More filters
Journal ArticleDOI
Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin
Jackson Michuda,Alessandra Breschi,Joshuah Kapilivsky,Kabir Manghnani,Calvin McCarter,Adam J. Hockenberry,Brittany Mineo,Catherine Igartua,Joel T. Dudley,Martin C. Stumpe,Nike Beaubier,Mohammmad Mehdi Shirazi,R. Jones,Elizabeth G. Morency,K. L. Blackwell,Justin Guinney,Karen Beauchamp,Timothy Taxter +17 more
TL;DR: The Tempus Tumor Origin (Tempus TO) assay as discussed by the authors is an RNA-sequencing-based machine learning classifier capable of discriminating between 68 clinically relevant cancer subtypes.
Posted ContentDOI
A community-based collaboration to build prediction models for short-term discontinuation of docetaxel in metastatic castration-resistant prostate cancer
Fatemeh Seyednasrollah,Devin C. Koestler,Tao Wang,Stephen R. Piccolo,Roberto Vega,Russell Greiner,Christiane Fuchs,Eyal Gofer,Luke Kumar,Russell D. Wolfinger,Kimberly Kanigel Winner,Chris Bare,Elias Chaibub Neto,Thomas Yu,Liji Shen,Kald Abdallah,Thea Norman,Gustavo Stolovitzky,Pcc-Dream Community,Howard R. Soule,Christopher Sweeney,Charles J. Ryan,Howard I. Scher,Oliver Sartor,Laura L. Elo,Fang Liz Zhou,Justin Guinney,James C. Costello +27 more
TL;DR: It is demonstrated that routinely collected clinical features can be used to prospectively inform clinicians of mCRPC patients’ risk to discontinue docetaxel treatment early due to adverse events and to the best of the knowledge is the first to establish performance benchmarks in this area.
Journal ArticleDOI
Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone.
Jackson Michuda,B. H. Park,Amy L. Cummings,Siddhartha Devarakonda,Bert H. O'Neil,Sumaiya Islam,Jerod Parsons,Rotem Ben-Shachar,Alessandra Breschi,Kimberly L. Blackwell,James L. Chen,Joel T. Dudley,Martin C. Stumpe,Justin Guinney,Ezra E.W. Cohen +14 more
TL;DR: The addition of RNA-seq to DNA-seq significantly increased the detection of fusion events and ability to match patients to targeted therapies, and support consideration of combined RNA-DNA-seq for standard-of-care fusion calling.
Journal ArticleDOI
Abstract 62: Temporal concordance rates of pathogenic variants in liquid biopsies taken after solid tissue NGS profiling in a real-world pan-cancer cohort
Matthew MacKay,Joshua Drews,Bonnie V. Dougherty,Duane C. Hassane,Chris Mason,Gaurav Khullar,Calvin Chao,Joel T. Dudley,Kim T. Blackwell,Nike Beaubier,Justin Guinney +10 more
TL;DR: The data strongly supports the use of matched solid and cfDNA testing, and further exploration of the clinical utility of cfDNA to identify pathogenic variants over the course of a patient’s disease, in one of the largest pan-cancer datasets.
Journal ArticleDOI
Characterizing the landscape of RING-type E3 ubiquitin transferase-altered (RNF43 alt) colorectal cancer (CRC) and defining unique subsets with potential therapeutic vulnerabilities in microsatellite instability-high (MSI-H) CRC.
Abdul Rafeh Naqash,Amin Nassar,Lisa Macera,E. Mauer,Justin Guinney,Calvin Chao,Elio Adib,Emanuel F. Petricoin,Arjun Mittra,Naoko Takebe,Timothy L. Cannon +10 more
TL;DR: In this article , the authors evaluated whether genomic and transcriptomic analysis of MSI-H RNF43 alt CRC defines distinct subsets with potential therapeutic vulnerabilities, and they found that RNF 43 alt are commonly present in MSI-h CRC with improved outcomes to immune checkpoint inhibitors (ICI).